Abstract: The extended release osmo-microsealed formulation includes three controlled release systems associated in series. First, there is an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure across the hydrophobic coating) and one or more binder polymers essentially to provide strength/hardness to the particle. Second, there is an outer solid continuous phase including one or more hydrophilic polymers, that is further compressed into a tablet. Third, there is an optional functional coat surrounding the tablet. The process/method for forming the Osmo-microsealed extended release delivery system and the process for using such system for treating human ailment/depression are also provided.